Palvella Therapeutics(PVLA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

PVLA Palvella Therapeutics

Closed 08-26 16:00:00 EDT

154.33

+6.09

+4.11%

盘后154.33

+0.000.00%

19:40 EDT

High154.75	Low144.22	Vol194.44K
Open148.18	D1 Closing148.24	Amplitude7.10%
Mkt Cap2.22B	Tradable Cap1.30B	Total Shares14.41M
T/O29.64M	T/O Rate2.32%	Tradable Shares8.40M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"PVLA","market":"US","secType":"STK","nameCN":"Palvella Therapeutics","latestPrice":154.33,"timestamp":1787774400000,"preClose":148.24,"halted":0,"volume":194444,"hourTrading":{"tag":"盘后","latestPrice":154.33,"preClose":154.33,"latestTime":"19:40 EDT","volume":8296,"amount":1280323.2631,"timestamp":1787787656925,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.04108202914193202,"floatShares":8398100,"shares":14408407,"eps":-4.897784,"marketStatus":"Closed","change":6.09,"latestTime":"08-26 16:00:00 EDT","open":148.18,"high":154.745,"low":144.22,"amount":29640432.80584,"amplitude":0.071,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-4.897784,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1787817600000},"marketStatusCode":5,"adr":0,"listingDate":1435636800000,"exchange":"NASDAQ","adjPreClose":148.24,"preHourTrading":{"tag":"盘前","latestPrice":147.31,"preClose":148.24,"latestTime":"08:44 EDT","volume":197,"amount":29193.561990000002,"timestamp":1787748272392,"change":-0.93,"changeRate":-0.006274,"amplitude":0.020103},"postHourTrading":{"tag":"盘后","latestPrice":154.33,"preClose":154.33,"latestTime":"19:40 EDT","volume":8296,"amount":1280323.2631,"timestamp":1787787656925,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.887401,"impliedVol":0.4976,"impliedVolPercentile":0.0279},"requestUrl":"/m/hq/s/PVLA/","defaultTab":"news","newsList":[{"id":"2661740234","title":"Palvella Therapeutics COO Kathleen Goin Reports Sale of 4,302 Common Shares Worth $654,184.41","url":"https://stock-news.laohu8.com/highlight/detail?id=2661740234","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661740234?lang=en_us&edition=fundamental","pubTime":"2026-08-21 04:06","pubTimestamp":1787256381,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics COO Kathleen Goin reports sale of 4,302 common shares worth $654,184.41Palvella Therapeutics COO Kathleen Goin exercised stock options on Aug. 19, 2026, acquiring 4,302 common sh","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260820:nNDL4yvj0V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Palvella Therapeutics COO Kathleen Goin Reports Sale of 4,302 Common Shares Worth $654,184.41","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657521017","title":"Analysts Are Bullish on Top Healthcare Stocks: Palvella Therapeutics (PVLA), Lifecore Biomedical (LFCR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657521017","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657521017?lang=en_us&edition=fundamental","pubTime":"2026-08-06 02:00","pubTimestamp":1785952826,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Palvella Therapeutics (PVLA) and Lifecore Biomedical...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-palvella-therapeutics-pvla-lifecore-biomedical-lfcr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-palvella-therapeutics-pvla-lifecore-biomedical-lfcr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PVLA","BK4212","BK4121","LFCR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657654223","title":"Palvella Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2657654223","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657654223?lang=en_us&edition=fundamental","pubTime":"2026-08-05 19:30","pubTimestamp":1785929400,"startTime":"0","endTime":"0","summary":"WAYNE, Pa., Aug.  05, 2026  (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the “Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commerciali","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/05/3339219/0/en/Palvella-Therapeutics-to-Participate-in-the-Canaccord-Genuity-46th-Annual-Growth-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PVLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657959638","title":"Palvella Therapeutics Charts Clear Path From Data To Launch","url":"https://stock-news.laohu8.com/highlight/detail?id=2657959638","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657959638?lang=en_us&edition=fundamental","pubTime":"2026-08-05 08:59","pubTimestamp":1785891560,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics, Inc. (($PVLA)) has held its Q2 earnings call. Read on for the main highlights of the call. Palvella Therapeutics’ latest ear...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/palvella-therapeutics-charts-clear-path-from-data-to-launch?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/palvella-therapeutics-charts-clear-path-from-data-to-launch?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DECU","PVLA","FEBU","PMDE","VOTE","JOYT","VGFPF","RGLO","GXDW","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657598577","title":"Cumberland Pharmaceuticals Q2 Loss Widens After Apotex Transaction","url":"https://stock-news.laohu8.com/highlight/detail?id=2657598577","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657598577?lang=en_us&edition=fundamental","pubTime":"2026-08-05 06:33","pubTimestamp":1785882830,"startTime":"0","endTime":"0","summary":"Cumberland Pharmaceuticals Q2 loss widens after Apotex transactionOverviewUS biopharma firm's Q2 revenue from continuing operations fell after Apotex transaction reclassified branded business as disco","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nL1N4411HO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INDV","BK4007","LPCN","CPIX","PVLA","BK4557"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657561508","title":"Spyre Therapeutics Q2 Loss Narrower than Expected; Sees Trial Readouts in 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2657561508","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657561508?lang=en_us&edition=fundamental","pubTime":"2026-08-05 04:14","pubTimestamp":1785874443,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics Q2 loss narrower than expected; sees trial readouts in 2026OverviewUS biotech firm's Q2 net loss and pretax loss were lower than analyst expectationsQ2 results included a $40 mln ga","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nL1N44113Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SYRE","LFSC","MEDI","PVLA","RYTM","DSGN","BK4588","BK4505","BK4585","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657056978","title":"Niagen Bioscience Q2 Net Sales Fall, Missing Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2657056978","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657056978?lang=en_us&edition=fundamental","pubTime":"2026-08-05 04:09","pubTimestamp":1785874173,"startTime":"0","endTime":"0","summary":"Niagen Bioscience Q2 net sales fall, missing estimatesOverviewU.S. bioscience firm's Q2 net sales declined and missed analyst expectationsQ2 net income was $1.0 mln, down from $3.6 mln a year earlierC","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nL1N44113L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4183","PVLA","BK4121","BK4139","BK4007","STOK","NAGE","LPCN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657569783","title":"Dianthus Therapeutics Q2 Net Loss Widens as R&D Costs Rise","url":"https://stock-news.laohu8.com/highlight/detail?id=2657569783","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657569783?lang=en_us&edition=fundamental","pubTime":"2026-08-05 04:09","pubTimestamp":1785874166,"startTime":"0","endTime":"0","summary":"Dianthus Therapeutics Q2 net loss widens as R&D costs riseOverviewUS biotech firm reported Q2 net loss widened to $50.2 mlnOperating expenses for Q2 rose, driven by higher R&D costs for clinical progr","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nL1N44113F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DNTH","BK4139","PVLA","BK4539","BK4505","KROS","IBRN","DSGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656155195","title":"Palvella Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2656155195","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656155195?lang=en_us&edition=fundamental","pubTime":"2026-08-04 21:31","pubTimestamp":1785850313,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics Inc reports results for the quarter ended June 30 - Earnings SummaryPalvella Therapeutics IncPVLA.OQreported a quarterly adjusted loss of $1.52 per share for the quarter ended Ju","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nL8N4411QW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PVLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656555999","title":"Palvella Therapeutics Q2 Net Loss Widens on Higher Expenses","url":"https://stock-news.laohu8.com/highlight/detail?id=2656555999","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656555999?lang=en_us&edition=fundamental","pubTime":"2026-08-04 20:08","pubTimestamp":1785845305,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics Q2 net loss widens on higher expensesOverviewUS biopharmaceutical firm's Q2 net loss widened yr/yr amid higher R&D and admin expensesCash and short-term investments totaled $250.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nL1N4410H3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA","TGTX","MEDI","BK4588","OCUL","RYTM","BK4139","BK4007","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656155375","title":"Palvella Therapeutics, Inc Q2 EPS USD -1.52","url":"https://stock-news.laohu8.com/highlight/detail?id=2656155375","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656155375?lang=en_us&edition=fundamental","pubTime":"2026-08-04 19:59","pubTimestamp":1785844761,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nPLXDC11N4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PVLA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656553532","title":"Earnings Flash (PVLA) Palvella Therapeutics Posts Q2 Net Loss $1.52 a Share, vs. FactSet Est of $1.07 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2656553532","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656553532?lang=en_us&edition=fundamental","pubTime":"2026-08-04 19:39","pubTimestamp":1785843579,"startTime":"0","endTime":"0","summary":"Earnings Flash (PVLA) Palvella Therapeutics Posts Q2 Net Loss $1.52 a Share, vs. FactSet Est of $1.07 Loss","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PVLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656558740","title":"Palvella Net Loss Widens 130.88% to $21.87 Million in Q2 FY26; R&D Expenses More than Doubled to $12.47 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2656558740","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656558740?lang=en_us&edition=fundamental","pubTime":"2026-08-04 19:32","pubTimestamp":1785843168,"startTime":"0","endTime":"0","summary":"Palvella net loss widens 130.88% to $21.87 million in Q2 FY26; R&D expenses more than doubled to $12.47 millionPalvella posted a Q2 net loss of $21.9 million, or $1.52 a share, widening from a $9.5 mi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nNDL151NZT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCDF","LU2210149790.SGD","SG9999014005.SGD","SG9999014013.SGD","NDAQ","IE00BGHQF748.EUR","LU0314104364.USD","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","LU2210150020.SGD","LU2095319765.USD","BK4585","IE00BN0W2W23.USD","PVLA","BK4139","BK4588","SG9999014021.USD","IE00B64PRP62.GBP","IE00BKPKM429.USD","BK4112","IE00B3QW5Z07.USD","SG9999014039.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656558784","title":"Palvella Therapeutics Q2 EPS $(1.52) Misses $(1.14) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2656558784","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656558784?lang=en_us&edition=fundamental","pubTime":"2026-08-04 19:30","pubTimestamp":1785843053,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics (NASDAQ:PVLA) reported quarterly losses of $(1.52) per share which missed the analyst consensus estimate of $(1.14) by 33.33 percent. This is a 76.74 percent decrease over losses of $(0.86) per","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/60901656/palvella-therapeutics-q2-eps-1-52-misses-1-14-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656055843","title":"Press Release: Palvella Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2656055843","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656055843?lang=en_us&edition=fundamental","pubTime":"2026-08-04 19:30","pubTimestamp":1785843000,"startTime":"0","endTime":"0","summary":"additional Phase 3 SELVA data during a late-breaking session at the. International Society for the Study of Vascular Anomalies World Congress. , including a statistically significant improvement in the. 6--11-year-old cohort and other supportive findings showing improvements","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03160","TM","BK4604","BK4585","BK4139","BK4588","BK4099","BK4555","PVLA","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655587463","title":"Palvella Therapeutics CSO Jeff Martini Presents at FDA Drug Repurposing Workshop","url":"https://stock-news.laohu8.com/highlight/detail?id=2655587463","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655587463?lang=en_us&edition=fundamental","pubTime":"2026-07-30 19:46","pubTimestamp":1785411970,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics CSO Jeff Martini presents at FDA drug repurposing workshopPalvella Therapeutics will attend an FDA public workshop on drug repurposing on Aug. 5, 2026, in Washington, D.C.Chief S","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260730:nNDL3gN1Nf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654004329","title":"Palvella Therapeutics to Host Second Quarter 2026 Financial Results and Corporate Update Conference Call on August 4, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2654004329","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654004329?lang=en_us&edition=fundamental","pubTime":"2026-07-28 19:30","pubTimestamp":1785238200,"startTime":"0","endTime":"0","summary":"WAYNE, Pa., July  28, 2026  (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the “Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commerciali","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/28/3334141/0/en/Palvella-Therapeutics-to-Host-Second-Quarter-2026-Financial-Results-and-Corporate-Update-Conference-Call-on-August-4-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HST","BK4588","BK4139","PVLA","BK4585","BK4218","BK4181"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653274204","title":"H.C. Wainwright says Palvella selloff ‘an overreaction’ to FDA’s BTD denial","url":"https://stock-news.laohu8.com/highlight/detail?id=2653274204","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653274204?lang=en_us&edition=fundamental","pubTime":"2026-07-22 01:15","pubTimestamp":1784654116,"startTime":"0","endTime":"0","summary":"H.C. Wainwright notes that on Monday, Palvella Therapeutics (PVLA) closed down 21% compared to the previous weeks close, which the firm believes wa...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/h-c-wainwright-says-palvella-selloff-an-overreaction-to-fdas-btd-denial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/h-c-wainwright-says-palvella-selloff-an-overreaction-to-fdas-btd-denial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU","BK4585","PVLA","BK4588","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653048422","title":"Palvella Therapeutics (PVLA) Receives a Rating Update from a Top Analyst","url":"https://stock-news.laohu8.com/highlight/detail?id=2653048422","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653048422?lang=en_us&edition=fundamental","pubTime":"2026-07-22 00:26","pubTimestamp":1784651166,"startTime":"0","endTime":"0","summary":"In a report released today, Ritu Baral from TD Cowen reiterated a Buy rating on Palvella Therapeutics, with a price target of $267.00. According to...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/palvella-therapeutics-pvla-receives-a-rating-update-from-a-top-analyst-blurbs-news-3?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/palvella-therapeutics-pvla-receives-a-rating-update-from-a-top-analyst-blurbs-news-3?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PVLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653201413","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: Palvella Therapeutics (PVLA), Neogen (NEOG) and ACADIA Pharmaceuticals (ACAD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2653201413","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653201413?lang=en_us&edition=fundamental","pubTime":"2026-07-22 00:11","pubTimestamp":1784650308,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Palvella Therapeutics (PVLA), Neogen (NEOG) and AC...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-palvella-therapeutics-pvla-neogen-neog-and-acadia-pharmaceuticals-acad-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-palvella-therapeutics-pvla-neogen-neog-and-acadia-pharmaceuticals-acad-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NEOG","LU2065169927.USD","BK4139","LU2065170008.USD","LU0128526141.USD","XBI","BK4581","HCSG","PVLA","ACAD","BK4588","LABU","BK4198","BK4137","LU2211817866.USD","LU2065171311.SGD","BK4585","LU2065171402.SGD","XLV","LU0029874061.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.pieris.com","stockEarnings":[{"period":"1week","weight":-0.0145},{"period":"1month","weight":0.0741},{"period":"3month","weight":0.2751},{"period":"6month","weight":-0.0007},{"period":"1year","weight":1.9571},{"period":"ytd","weight":0.4163}],"compareEarnings":[{"period":"1week","weight":-0.002},{"period":"1month","weight":0.0365},{"period":"3month","weight":0.0206},{"period":"6month","weight":0.1111},{"period":"1year","weight":0.1921},{"period":"ytd","weight":0.1232}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Pieris Pharmaceuticals, Inc., a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc.; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies. The company was founded in 2001 and is headquartered in Boston, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.636364,"avgChangeRate":0.069248},{"month":2,"riseRate":0.545455,"avgChangeRate":0.088954},{"month":3,"riseRate":0.454545,"avgChangeRate":0.004194},{"month":4,"riseRate":0.272727,"avgChangeRate":-0.071975},{"month":5,"riseRate":0.454545,"avgChangeRate":0.145935},{"month":6,"riseRate":0.454545,"avgChangeRate":-0.054496},{"month":7,"riseRate":0.666667,"avgChangeRate":0.148037},{"month":8,"riseRate":0.666667,"avgChangeRate":0.113674},{"month":9,"riseRate":0.363636,"avgChangeRate":-0.090465},{"month":10,"riseRate":0.272727,"avgChangeRate":-0.050324},{"month":11,"riseRate":0.545455,"avgChangeRate":0.066832},{"month":12,"riseRate":0.363636,"avgChangeRate":-0.051298}],"exchange":"NASDAQ","name":"Palvella Therapeutics","nameEN":"Palvella Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Palvella Therapeutics(PVLA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Palvella Therapeutics(PVLA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Palvella Therapeutics,PVLA,Palvella Therapeutics股票,Palvella Therapeutics股票老虎,Palvella Therapeutics股票老虎国际,Palvella Therapeutics行情,Palvella Therapeutics股票行情,Palvella Therapeutics股价,Palvella Therapeutics股市,Palvella Therapeutics股票价格,Palvella Therapeutics股票交易,Palvella Therapeutics股票购买,Palvella Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Palvella Therapeutics(PVLA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Palvella Therapeutics(PVLA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}